CytomX Therapeutics, Inc. (CTMX)

Every figure this model derived for CTMX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 74,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 330,280,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 373,155,000 AssetsCurrent 2026-06-30
current liabilities 39,861,000 LiabilitiesCurrent 2026-06-30
equity 302,068,000 StockholdersEquity 2026-06-30
ocf -82,408,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 18,302,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 10,146,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CTMX on one particular measure came for.

RatioValue
cash operating margin-414.2
current ratio23.64
current ratio reported9.36
deferred revenue growth9.17
dilution pct62.82
fcf margin-450.67
growth cv3.36
operating margin-476.19
owner earnings margin-506.11
revenue growth-87.03
revenue growth per share-92.03
rule of 40-563.22
sbc pct revenue55.44

What to be careful about

What this model itself distrusts about CTMX's figures. Written by the derivation as it ran, not added afterwards.